Results 11 to 20 of about 119,702 (338)

A potential biomarker of cognitive impairment: The olfactory dysfunction and its genes expression

Annals of Clinical and Translational Neurology, Volume 9, Issue 12, Page 1884-1897, December 2022., 2022
Abstract Objective Accumulation evidence has reported that olfactory impairment may be an essential clinical marker and predictor of mild cognitive impairment or Alzheimer's disease. Method Participants were enrolled in the population‐based, prospective study in Fuxin county, Liaoning province, China between 2019 and 2021.
Jiayi Song, Jiahui Xu, Wei Yuan, Ruixue Li, Hui Guo, Hanshu Gao, Cuiying Gu, Wenjing Feng, Yanan Ma, Haiqiang Guo, Zhaoqing Sun, Liqiang Zheng   +11 more
wiley   +1 more source

Parkinson′s disease

Annals of Indian Academy of Neurology, 2011
These guidelines present evidence for interventions to manage early stage, uncomplicated Parkinson's Disease. This includes pharmacological and non-pharmacological interventions. The evidence for pharmacological agents to provide neuroprotection or disease modification, such as a delay in disease progression, is discussed, with no trials demonstrating ...
Behari, Madhuri, Bhattacharyya, Kalyan Brata, Borgohain, Rupam, Das, Shyamal Kumar, Ghosh, Bhaskar, Kishore, Asha, Krishnan, Syam, Mridula, K Rukmini, Muthane, Uday, Pal, Pramod Kumar, Sankhla, Charulata, Shukla, Garima   +11 more
openaire   +8 more sources

Differential serum microRNAs in premotor LRRK2 G2019S carriers from Parkinson’s disease

npj Parkinson's Disease, 2023
The LRRK2 G2019S pathogenic mutation causes LRRK2-associated Parkinson’s disease (L2PD) with incomplete penetrance. LRRK2 non-manifesting carriers (L2NMC) are at PD high risk but predicting pheno-conversion is challenging given the lack of progression ...
Marta Soto, Manel Fernández, Paloma Bravo, Sara Lahoz, Alicia Garrido, Antonio Sánchez-Rodríguez, María Rivera-Sánchez, María Sierra, Paula Melón, Ana Roig-García, Anna Naito, Bradford Casey, Jordi Camps, Eduardo Tolosa, María-José Martí, Jon Infante, Mario Ezquerra, Rubén Fernández-Santiago   +17 more
doaj   +1 more source

Transcriptome analysis in LRRK2 and idiopathic Parkinson’s disease at different glucose levels

npj Parkinson's Disease, 2021
Type-2 diabetes (T2D) and glucose metabolic imbalances have been linked to neurodegenerative diseases, including Parkinson’s disease (PD). To detect potential effects of different glucose levels on gene expression, by RNA-seq we analyzed the ...
Rubén Fernández-Santiago, Anna Esteve-Codina, Manel Fernández, Francesc Valldeoriola, Almudena Sanchez-Gómez, Esteban Muñoz, Yaroslau Compta, Eduardo Tolosa, Mario Ezquerra, María J. Martí   +9 more
doaj   +1 more source

Deep Learning Predicts Prevalent and Incident Parkinson's Disease From UK Biobank Fundus Imaging [PDF]

, 2023
Parkinson's disease is the world's fastest-growing neurological disorder. Research to elucidate the mechanisms of Parkinson's disease and automate diagnostics would greatly improve the treatment of patients with Parkinson's disease. Current diagnostic methods are expensive and have limited availability.
arxiv   +1 more source

Optimization of cognitive assessment in Parkinsonisms by applying artificial intelligence to a comprehensive screening test

npj Parkinson's Disease, 2022
The assessment of cognitive deficits is pivotal for diagnosis and management in patients with parkinsonisms. Low levels of correspondence are observed between evaluations assessed with screening cognitive tests in comparison with those assessed with in ...
Paola Ortelli, Davide Ferrazzoli, Viviana Versace, Veronica Cian, Marianna Zarucchi, Anna Gusmeroli, Margherita Canesi, Giuseppe Frazzitta, Daniele Volpe, Lucia Ricciardi, Raffaele Nardone, Ingrid Ruffini, Leopold Saltuari, Luca Sebastianelli, Daniele Baranzini, Roberto Maestri   +15 more
doaj   +1 more source

Microbiota Dysbiosis in Parkinson Disease—In Search of a Biomarker

Biomedicines, 2022
Numerous studies have highlighted the role of the gastrointestinal system in Parkinson disease pathogenesis. It is likely triggered by proinflammatory markers produced by specific gut bacteria. This review’s aim is to identify gut bacterial biomarkers of
Julia Maya Nowak, Mateusz Kopczyński, Andrzej Friedman, Dariusz Koziorowski, Monika Figura   +4 more
doaj   +1 more source

No sex differences in use of dopaminergic medication in early Parkinson disease in the US and Canada - baseline findings of a multicenter trial. [PDF]

PLoS ONE, 2014
Sex differences in Parkinson disease clinical features have been reported, but few studies have examined sex influences on use of dopaminergic medication in early Parkinson disease.
Chizoba C Umeh, Adriana Pérez, Erika F Augustine, Rohit Dhall, Richard B Dewey, Zoltan Mari, David K Simon, Anne-Marie A Wills, Chadwick W Christine, Jay S Schneider, Oksana Suchowersky   +10 more
doaj   +1 more source

Noradrenaline and Parkinson's Disease [PDF]

Frontiers in Systems Neuroscience, 2011
Parkinson's disease (PD) is characterized by the degeneration of dopamine (DA) neurons in the substantia nigra pars compacta, and motor symptoms including bradykinesia, rigidity, and tremor at rest. These symptoms are exhibited when striatal dopamine concentration has decreased by around 70%.
Claire eDelaville, Philippe eDe Deurwaerdère, Abdelhamid eBenazzouz, Abdelhamid eBenazzouz   +3 more
openaire   +5 more sources

Parkinson’s Disease and Autophagy [PDF]

Parkinson's Disease, 2012
It is generally accepted that a correlation between neurodegenerative disease and protein aggregation in the brain exists; however, a causal relationship has not been elucidated. In neurons, failure of autophagy may result in the accumulation of aggregate-prone proteins and subsequent neurodegeneration.
Ana María Sánchez-Pérez, Ana María Sánchez-Pérez, Berta Claramonte-Clausell, Maria Herrero, Maria Herrero, Juan Vicente Sánchez-Andrés   +5 more
openaire   +5 more sources